Rep. Gilbert Ray Cisneros, Jr. Sells Bristol Myers Squibb Company (NYSE:BMY) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol Myers Squibb stock on October 9th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of CommVault Systems (NASDAQ:CVLT) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Cohen & Steers (NYSE:CNS) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of UFP Industries (NASDAQ:UFPI) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Enerpac Tool Group (NYSE:EPAC) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Iberdrola (OTCMKTS:IBDSF) on 10/21/2025.

Bristol Myers Squibb Trading Up 3.4%

NYSE BMY traded up $1.58 during trading hours on Monday, hitting $47.83. The company’s stock had a trading volume of 27,195,922 shares, compared to its average volume of 13,890,074. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The firm has a market capitalization of $97.37 billion, a P/E ratio of 19.29, a PEG ratio of 2.23 and a beta of 0.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a fifty day moving average of $45.28 and a 200 day moving average of $46.56.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Friday, October 3rd were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.2%. The ex-dividend date of this dividend was Friday, October 3rd. Bristol Myers Squibb’s payout ratio is 83.78%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Scotiabank assumed coverage on shares of Bristol Myers Squibb in a report on Thursday, November 13th. They set a “sector perform” rating and a $45.00 price objective for the company. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Four research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $54.42.

Institutional Trading of Bristol Myers Squibb

A number of large investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. bought a new position in Bristol Myers Squibb in the third quarter valued at approximately $12,664,000. Achmea Investment Management B.V. increased its position in shares of Bristol Myers Squibb by 16.2% during the third quarter. Achmea Investment Management B.V. now owns 1,009,890 shares of the biopharmaceutical company’s stock worth $45,547,000 after acquiring an additional 140,840 shares in the last quarter. Ariadne Wealth Management LP raised its holdings in shares of Bristol Myers Squibb by 17.5% during the third quarter. Ariadne Wealth Management LP now owns 8,072 shares of the biopharmaceutical company’s stock worth $393,000 after acquiring an additional 1,200 shares during the period. WBI Investments LLC lifted its position in Bristol Myers Squibb by 205.6% in the 3rd quarter. WBI Investments LLC now owns 59,803 shares of the biopharmaceutical company’s stock valued at $2,697,000 after acquiring an additional 40,237 shares in the last quarter. Finally, Tweedy Browne Co LLC boosted its stake in Bristol Myers Squibb by 101.4% in the 3rd quarter. Tweedy Browne Co LLC now owns 14,466 shares of the biopharmaceutical company’s stock worth $652,000 after purchasing an additional 7,282 shares during the period. 76.41% of the stock is owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.